Stem definition | Drug id | CAS RN |
---|---|---|
1211 | 2709-56-0 |
Dose | Unit | Route |
---|---|---|
6 | mg | O |
4 | mg | P |
Property | Value | Reference |
---|---|---|
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
CL (Clearance) | 4.14 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 34.20 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Jan. 1, 1964 | YEAR INTRODUCED |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Blood prolactin abnormal | 483.15 | 38.66 | 82 | 2979 | 1207 | 46681794 |
Anosognosia | 482.92 | 38.66 | 83 | 2978 | 1322 | 46681679 |
Disturbance in social behaviour | 459.00 | 38.66 | 82 | 2979 | 1649 | 46681352 |
Sexual dysfunction | 432.15 | 38.66 | 82 | 2979 | 2321 | 46680680 |
Metabolic disorder | 382.08 | 38.66 | 82 | 2979 | 4350 | 46678651 |
Personality change | 373.63 | 38.66 | 83 | 2978 | 5175 | 46677826 |
Dystonia | 296.63 | 38.66 | 80 | 2981 | 11177 | 46671824 |
Suicide attempt | 281.77 | 38.66 | 113 | 2948 | 54923 | 46628078 |
Dyskinesia | 264.46 | 38.66 | 91 | 2970 | 28834 | 46654167 |
Sedation | 256.64 | 38.66 | 84 | 2977 | 22826 | 46660175 |
Schizophrenia | 166.43 | 38.66 | 48 | 3013 | 8520 | 46674481 |
Blood glucose increased | 163.57 | 38.66 | 84 | 2977 | 71929 | 46611072 |
Insurance issue | 93.48 | 38.66 | 22 | 3039 | 1756 | 46681245 |
Extrapyramidal disorder | 67.43 | 38.66 | 26 | 3035 | 11242 | 46671759 |
Condition aggravated | 60.34 | 38.66 | 77 | 2984 | 244975 | 46438026 |
Drug ineffective | 54.10 | 38.66 | 129 | 2932 | 677709 | 46005292 |
Suicidal ideation | 52.11 | 38.66 | 37 | 3024 | 56345 | 46626656 |
Hallucination, auditory | 44.34 | 38.66 | 19 | 3042 | 10737 | 46672264 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Akathisia | 172.31 | 45.77 | 48 | 2474 | 5856 | 29944100 |
Suicide attempt | 168.33 | 45.77 | 75 | 2447 | 36622 | 29913334 |
Antipsychotic drug level below therapeutic | 165.34 | 45.77 | 35 | 2487 | 1337 | 29948619 |
Therapeutic product effect variable | 164.91 | 45.77 | 35 | 2487 | 1354 | 29948602 |
Anosognosia | 163.74 | 45.77 | 31 | 2491 | 663 | 29949293 |
Blood prolactin abnormal | 161.71 | 45.77 | 31 | 2491 | 710 | 29949246 |
Obsessive-compulsive disorder | 159.93 | 45.77 | 42 | 2480 | 4099 | 29945857 |
Disinhibition | 152.95 | 45.77 | 35 | 2487 | 1922 | 29948034 |
Disturbance in social behaviour | 140.51 | 45.77 | 31 | 2491 | 1440 | 29948516 |
Euphoric mood | 130.28 | 45.77 | 36 | 2486 | 4254 | 29945702 |
Increased appetite | 125.05 | 45.77 | 37 | 2485 | 5580 | 29944376 |
Metabolic disorder | 112.85 | 45.77 | 31 | 2491 | 3580 | 29946376 |
Sexual dysfunction | 109.84 | 45.77 | 34 | 2488 | 5967 | 29943989 |
Dyskinesia | 104.34 | 45.77 | 46 | 2476 | 21788 | 29928168 |
Dystonia | 97.48 | 45.77 | 35 | 2487 | 9692 | 29940264 |
Personality change | 88.13 | 45.77 | 27 | 2495 | 4573 | 29945383 |
Weight increased | 84.32 | 45.77 | 61 | 2461 | 74852 | 29875104 |
Sedation | 83.07 | 45.77 | 36 | 2486 | 16337 | 29933619 |
Hangover | 77.37 | 45.77 | 18 | 2504 | 1060 | 29948896 |
Schizophrenia | 73.83 | 45.77 | 28 | 2494 | 9020 | 29940936 |
Obesity | 64.51 | 45.77 | 25 | 2497 | 8530 | 29941426 |
Drug ineffective | 63.86 | 45.77 | 107 | 2415 | 340280 | 29609676 |
Leukopenia | 63.72 | 45.77 | 46 | 2476 | 56113 | 29893843 |
Dyslipidaemia | 62.62 | 45.77 | 22 | 2500 | 5705 | 29944251 |
Therapeutic product effect incomplete | 55.85 | 45.77 | 35 | 2487 | 33799 | 29916157 |
Aggression | 50.64 | 45.77 | 34 | 2488 | 36873 | 29913083 |
Source | Code | Description |
---|---|---|
ATC | N05AF01 | NERVOUS SYSTEM PSYCHOLEPTICS ANTIPSYCHOTICS Thioxanthene derivatives |
CHEBI has role | CHEBI:35469 | thymoanaleptics |
CHEBI has role | CHEBI:35474 | minor tranquilisers |
CHEBI has role | CHEBI:37890 | alpha-adrenoceptor antagonists |
CHEBI has role | CHEBI:48561 | dopamine blocker |
CHEBI has role | CHEBI:65190 | typical antipsychotic drug |
CHEBI has role | CHEBI:76779 | prolyl oligopeptidase (ec 3.4.21.26) inhibitor |
MeSH PA | D014150 | Antipsychotic Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D002492 | Central Nervous System Depressants |
MeSH PA | D015259 | Dopamine Agents |
MeSH PA | D018492 | Dopamine Antagonists |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D011619 | Psychotropic Drugs |
MeSH PA | D014149 | Tranquilizing Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Schizophrenia | indication | 58214004 | DOID:5419 |
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.19 | Basic |
pKa2 | 4.19 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
D(1A) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.40 | IUPHAR | IUPHAR | |||
D(2) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.82 | IUPHAR | IUPHAR | |||
D(3) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.96 | IUPHAR | ||||
D(1B) dopamine receptor | GPCR | ANTAGONIST | Ki | 8.10 | IUPHAR | ||||
Alpha-1A adrenergic receptor | GPCR | WOMBAT-PK | |||||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 7.06 | PDSP | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.10 | PDSP | |||||
Solute carrier family 22 member 1 | Transporter | IC50 | 4.05 | CHEMBL | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | IC50 | 8.65 | CHEMBL | |||||
Histamine H1 receptor | GPCR | Ki | 9.07 | PDSP | |||||
D(4) dopamine receptor | GPCR | Ki | 8.80 | PDSP | |||||
Dopamine receptor | GPCR | IC50 | 8.52 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | IC50 | 9.52 | CHEMBL | |||||
D(1A) dopamine receptor | GPCR | Ki | 7.75 | CHEMBL |
ID | Source |
---|---|
D01044 | KEGG_DRUG |
2413-38-9 | SECONDARY_CAS_RN |
C0016272 | UMLSCUI |
CHEBI:93235 | CHEBI |
CHEMBL42055 | ChEMBL_ID |
CHEMBL54661 | ChEMBL_ID |
DB00875 | DRUGBANK_ID |
D005475 | MESH_DESCRIPTOR_UI |
948 | IUPHAR_LIGAND_ID |
1745 | INN_ID |
21HMQ851IS | UNII |
5281881 | PUBCHEM_CID |
235742 | RXNORM |
003477 | NDDF |
003479 | NDDF |
387567006 | SNOMEDCT_US |
442075003 | SNOMEDCT_US |
96220002 | SNOMEDCT_US |
None